Chinese Drug Co. Chief Must Testify In Tainted Valsartan MDL

By Mike Curley · June 22, 2021, 3:57 PM EDT

The special master in multidistrict litigation alleging that pharmaceutical companies sold generic drugs containing the active ingredient valsartan that were tainted with carcinogens ruled on Tuesday that the president of Zhejiang...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

VALSARTAN LOSARTAN AND IRBESARTAN PRODUCTS LIABILITY LITIGATION

Case Number

Court

New Jersey

Nature of Suit

Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability

Date Filed

February 14, 2019

Recent Articles By Mike

July 26, 2024
Judge Allows Emotional Damages In Deaf Patient's Bias Suit
July 16, 2024
3rd Circ. Backs Tossing Over 1K Suits In Merck Vaccine MDL
June 28, 2024
Philips Gets OK For $25M Med Monitoring Deal In CPAP MDL
June 27, 2024
Whole Foods, Hain Want Full 5th Circ. Review Of Baby Food Suit
June 20, 2024
11th Circ. Upholds $2.5M Pelvic Mesh Verdict, Rules Suit Timely
June 18, 2024
COVID Test Maker Can't Shake All Of $30M Faulty Kit Suit
May 31, 2024
Weight Loss Drug Caused Stomach Paralysis, Suit Says
May 22, 2024
NC Panel Revives Retention Claim In Faulty Back Surgery Suit
May 21, 2024
Counties Not 'Persons' In Texas Opioid MDL Appeal
May 16, 2024
NY High Court Blocks Doctor's Hospital Shooting Injury Suit